Dirk Weber

1.1k total citations
35 papers, 709 citations indexed

About

Dirk Weber is a scholar working on Oncology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Dirk Weber has authored 35 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Organic Chemistry and 10 papers in Molecular Biology. Recurrent topics in Dirk Weber's work include Lung Cancer Treatments and Mutations (7 papers), HER2/EGFR in Cancer Research (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Dirk Weber is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), HER2/EGFR in Cancer Research (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Dirk Weber collaborates with scholars based in Germany, United States and Switzerland. Dirk Weber's co-authors include J. Tillner, Frank Czubayko, Hartmut Juhl, Anton Wellstein, Peter Eickelmann, Horst Kessler, Jack P. Antel, C Berger, Christian Kollmannsberger and Federico Rojo and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry and British Journal of Cancer.

In The Last Decade

Dirk Weber

33 papers receiving 682 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dirk Weber Germany	14	305	281	142	132	78	35	709
Jianguo Ma China	18	359 1.2×	487 1.7×	131 0.9×	72 0.5×	25 0.3×	49	879
Suzanne Leijen Netherlands	13	728 2.4×	770 2.7×	93 0.7×	227 1.7×	77 1.0×	19	1.3k
Anna Fioravanti Italy	21	395 1.3×	326 1.2×	192 1.4×	81 0.6×	24 0.3×	38	896
Tiago De Oliveira Germany	16	218 0.7×	371 1.3×	42 0.3×	76 0.6×	79 1.0×	25	766
Giovanni Santelli Italy	18	377 1.2×	523 1.9×	82 0.6×	57 0.4×	148 1.9×	41	1.1k
Ulrich Klar Germany	17	482 1.6×	355 1.3×	106 0.7×	214 1.6×	164 2.1×	41	951
Hans Petter Eikesdal Norway	19	412 1.4×	496 1.8×	106 0.7×	37 0.3×	49 0.6×	41	987
Chunrong Li United States	19	556 1.8×	486 1.7×	256 1.8×	97 0.7×	46 0.6×	38	1.1k
Eugenia Kraynov United States	16	654 2.1×	857 3.0×	72 0.5×	56 0.4×	111 1.4×	25	1.4k
Gareth Hughes United Kingdom	13	627 2.1×	694 2.5×	321 2.3×	99 0.8×	71 0.9×	22	1.3k

Countries citing papers authored by Dirk Weber

Since Specialization

Citations

This map shows the geographic impact of Dirk Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Weber more than expected).

Fields of papers citing papers by Dirk Weber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Weber. The network helps show where Dirk Weber may publish in the future.

Co-authorship network of co-authors of Dirk Weber

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Weber. A scholar is included among the top collaborators of Dirk Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Weber. Dirk Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frutos, Rogelio P., Dirk Weber, Tobias Brodmann, et al.. (2024). Development of a Scalable Asymmetric Process for the Synthesis of Selective PDE4B Inhibitor Nerandomilast (BI 1015550). Organic Process Research & Development. 28(9). 3745–3751.

Schindler, Christoph, Jacek Mikosiński, Igor Mierau, et al.. (2024). Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study. Therapeutic Advances in Endocrinology and Metabolism. 15. 2455663414–2455663414. 5 indexed citations

Weber, Dirk, Rajwinder Lehal, Viktoras Frismantas, et al.. (2018). Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor targeting the NOTCH transcription complex. Annals of Oncology. 29. iii14–iii14. 3 indexed citations

García, José Manuel Pérez, Javier Cortés, Anastasios Stathis, et al.. (2018). First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.. Journal of Clinical Oncology. 36(15_suppl). TPS2619–TPS2619. 9 indexed citations

Spriano, Filippo, Chiara Tarantelli, Alberto J. Arribas, et al.. (2018). Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103. Molecular Cancer Therapeutics. 17(1_Supplement). B061–B061. 4 indexed citations

Colombo, Nicoletta, E. Kutarska, Meletios Α. Dimopoulos, et al.. (2012). Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer. Journal of Clinical Oncology. 30(31). 3841–3847. 95 indexed citations

Oehler, Christoph, Karl Frei, Elisabeth J. Rushing, et al.. (2012). Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial. Oncology. 83(1). 1–9. 37 indexed citations

Eigl, Bernhard J., Peter Venner, Sébastien J. Hotte, et al.. (2011). A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Annals of Oncology. 23(1). 53–58. 29 indexed citations

Souza, Paul L. de, Begoña Mellado, C. Pfister, et al.. (2010). Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 28(15_suppl). 4553–4553. 6 indexed citations

10.

Kollmannsberger, Christian, Marcus M. Schittenhelm, Friedemann Honecker, et al.. (2006). A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Annals of Oncology. 17(6). 1007–1013. 79 indexed citations

11.

Graeven, Ullrich, B. Kremer, B. Killing, et al.. (2006). Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. British Journal of Cancer. 94(9). 1293–1299. 83 indexed citations

12.

Seiden, Michael V., H. A. Burris, U. Matulonis, et al.. (2005). A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies. Journal of Clinical Oncology. 23(16_suppl). 3151–3151. 8 indexed citations

13.

Maslennikova, Vera I., L. K. Vasyanina, Konstantin А. Lyssenko, et al.. (2003). Cyclophosphorylation of polyphenols by diamidoarylphosphites. Tetrahedron. 59(10). 1753–1761. 5 indexed citations

14.

Gloede, Jörg, et al.. (2003). A Hexacoordinated P-Bridged Calixarene Derivative -- Phosphorylation of p-tert -Butylthiacalix[4]arene. Phosphorus, sulfur, and silicon and the related elements. 178(4). 923–927. 5 indexed citations

15.

Maslennikova, Vera I., L. K. Vasyanina, И. Бауер, et al.. (2003). Approaches to the Synthesis of Conjugates of Phosphocavitands and Natural Compounds. Phosphorus, sulfur, and silicon and the related elements. 178(7). 1489–1505. 1 indexed citations

16.

Sipos, Bence, Dirk Weber, Hendrik Ungefroren, et al.. (2002). Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: An in vitro and in vivo study. International Journal of Cancer. 102(6). 592–600. 29 indexed citations

17.

Weber, Dirk, C Berger, Timo Heinrich, et al.. (2002). Systematic optimization of a lead‐structure identities for a selective short peptide agonist for the human orphan receptor BRS‐3. Journal of Peptide Science. 8(8). 461–475. 20 indexed citations

18.

Leverd, P.C., et al.. (2000). Inclusion of HNEt₃⁺in an acyclic tetraphenolate. Acta Crystallographica Section C Crystal Structure Communications. 56(8). 997–998. 1 indexed citations

19.

Антипин, И. С., Ivan I. Stoikov, А.Т. Губайдуллин, et al.. (1999). Phosphorylation of p-tert-butylthiocalix[4]arene: Reaction with phosphorus trichloride. Tetrahedron Letters. 40(48). 8461–8464. 16 indexed citations

20.

Stolp, W., Volker Thiemann, Dirk Weber, & Ch. Weiß. (1971). Measurements of the criticalPO2 of renal mitochondria. Pflügers Archiv - European Journal of Physiology. 323(3). 250–257. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact